阿昔莫司联合普伐他汀治疗老年混合型高脂血症的疗效与安全性

目的观察阿昔莫司联合普伐他汀治疗老年冠心病合并混合型高脂血症的疗效与安全性。方法2006年2月至2008年1月在中日友好医院高干医疗科诊断为冠心病合并混合型高脂血症的71例患者，年龄在60～75岁，其中分为阿昔莫司＋普伐他汀联合治疗组及单用普伐他汀治疗组，进行6个月的治疗随访。比较两组治疗前后的血脂水平、血脂达标率以及不良反应的发生情况。结果①6个月后，阿昔莫司＋普伐他汀联合组治疗TC、TG、LDL—C显著降低，HDL—C水平（P〈0．05）升高。而普伐他汀治疗TC、LDL—C水平显著降低，对TG、HDL—C影响不大。（④治疗6个月后，联合治疗组TC、LDL—C、HDL—C、TG的达标率分别为78.3％，75．7％，49．5％，59．4％，均高于普伐他汀组（P〈0．05）。结论阿昔莫司联合普伐他汀治疗老年冠心病合并混合型高脂血症的患者，可以全面改善患者的血脂谱，使血脂达标率明显提高，具有良好的安全性和耐受性。

Efficacy and Safety of Acipimox Plus Pravastatin for Treating the Elderly Patients with Combined Hyperlipidemia

Objective To observe the efficacy and safety of acipimox plus pravastatin for treating the elderly patients with combined hyperlipidemia. Methods All the patients with coronary heart disease and combined hyperlipidemia were divided two groups during February 2005 and January 2008. One group were received by the therapy of acipimox plus pravastatin, the other were received by pravastatin treatment.The level of cholesterol,the rate of achieving cholesterol goal and the adverse events were followed up after six months. Results ①The TC ,TG and LDL-C of treatment groups decreased significandy after six months. The level of HDL-C increased （P〈0.05）. The TC and LDL-C of pravastatin treatment groups decreased significantly. The TG and HDL-C changed a little. ②The standardized rates of TC ,LDL-C,HDL-C and TG in the combination-therapy group amounted to 78.5%,75.7%,49.5% and 59.4% respectively,which were superior to the results of monotherapy. Conclusion Acipimox plus pravastatin for treating the elderly patients with coronary heart disease and combined hyperlipidemia is safe and tolerable,which may produce a more global and effective improvement in blood lipid levels than monotherapy.